Citizens Initiates Coverage On Microbot Medical with Market Outperform Rating, Announces Price Target of $2.5
Citizens analyst Daniel Stauder initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Market Outperform rating and announces Price Target of $2.5.
Share
Why It Matters
An expert analyst says Microbot Medical looks promising and sets a price goal of $2.5. When analysts start watching a stock, it means they think it's worth studying closely.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.